Proteomic Stratification Test Can Help Guide Second-Line Treatment of NSCLC
A simple serum protein test can help guide treatment decisions between chemotherapy and erlotinib as second-line therapy for patients with non-small-cell lung cancer, according to results of a phase III study presented at ASCO.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva